Center-Authored Papers

Filters: Author is Williams, Constance  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Zolla-Pazner S, Decamp AC, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris DE, Tomaras G, Rao M, Billings E et al..  2013.  Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.. PloS one. 8(1):e53629. Abstract
Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self SG, Williams C, Gorny MK, Zolla-Pazner S.  2010.  Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes.. PloS one. 5(4):e10254. Abstract
I
Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam MS, Evans DT, Montefiori DC, Karnasuta C, Sutthent R et al..  2012.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.. The New England journal of medicine. 366(14):1275-86. Abstract
T
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X et al..  2012.  The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120.. AIDS research and human retroviruses. 28(11):1444-57. Abstract
V
Zolla-Pazner S, Edlefsen PT, Rolland M, Kong X-P, DeCamp A, Gottardo R, Williams C, Tovanabutra S, Sharpe-Cohen S, Mullins JI et al..  2014.  Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting Viruses.. EBioMedicine. 1(1):37-45. Abstract
Zolla-Pazner S, DeCamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA et al..  2014.  Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.. PloS one. 9(2):e87572. Abstract